Hemay Pharmaceutical PTY. LTD.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tianjin China (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2015
NCT02467569
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Ganzhou Hemay Pharmaceutical Co., Ltd | Hemay Pharmaceutical PTY. LTD. | Tianjin Hemay Bio-Tech Co., Ltd | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | Tianjin Hemay Pharmaceutical Co.,Ltd | Tianjin Hemay Pharmaceutical Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (4)

capecitabine (xeloda) (1 trial)

hemay005 (13 trials)

hemay-022 (4 trials)

lapatinib (tykerb) (1 trial)

Drugs in Phase 2 Trials (2)

hemay007 (3 trials)

hemay808 (2 trials)

Drugs in Phase 1 Trials (4)

exemestane (aromasin) (1 trial)

hemay020 (1 trial)

hemay102 (1 trial)

pacritinib (Vonjo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Behcet Syndrome (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Inflammatory Bowel Diseases (Phase 1)

Neoplasms (Phase 1)

Psoriasis (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial APIs: 10